Initial Safety and Efficacy of ¹⁷⁷Lu-NYM032 in Progressive mCRPC: A Phase I/II Study (EANM 2026) - Sep 29, 2026 - Abstract #OP-462; Pres time: Oct 19, 2026; 03:00 PM - 04:30 PM; Location: Hall G1; "Overall, 177Lu-NYM032 demonstrated a manageable safety profile very similar to 177Lu-PSMA-617, and no unexpected or different safety signal was observed. 177Lu-NYM032 demonstrated encouraging therapeutic efficacy with a manageable safety profile, supporting further clinical development in mCRPC."
Clinical • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor • Xerostomia
|
|
O. Sartor 1; Y. Wang 2; L. Hou 2; Q. Xu 2; X. Xue 3, 4; J. Pan 5; X. Lin 5; P. Fang 5; P. Mozley 5; C. Yu 2, 6
|